

# THE ROLE OF CONNECTIVE TISSUE DYSPLASIA IN UTERINE SCAR INSUFFICIENCY AFTER CESAREAN SECTION

Sidikov Akmal Abdikaxarovich

DSc, Professor of Fergana Medical Institute of Public Health

G'ulomova Ra'noxon Islomjonovna

Assistant of Fergana Medical Institute of Public Health

## Abstract

This review explores the key role of connective tissue dysplasia in the development of uterine scar defects after cesarean section. Abnormal collagen synthesis and extracellular matrix disruption impair wound healing, increasing the risk of scar dehiscence and rupture, especially in patients with hereditary connective tissue disorders. Molecular factors such as imbalanced collagen types and altered enzyme activity contribute to poor tissue repair. Improved diagnostics using biomarkers, imaging, and genetic screening help identify high-risk individuals. Current management highlights multidisciplinary care, preconception counseling, and personalized delivery planning. This synthesis supports better clinical decisions and improved outcomes.

**Keywords:** Connective tissue dysplasia, uterine scar insufficiency, cesarean section, collagen metabolism, wound healing, maternal morbidity.

## Introduction

Today's obstetric practice faces an unprecedented challenge with the continuously rising cesarean section rates globally, reaching approximately 32% in developed countries and creating a substantial population of women with uterine scars who require specialized care in subsequent pregnancies. The integrity of uterine scar tissue following cesarean delivery represents a critical determinant of maternal and perinatal outcomes, with scar insufficiency contributing to severe complications including uterine rupture, abnormal placentation, and life-threatening hemorrhage. Among the multiple factors influencing scar healing and long-term integrity, connective tissue dysplasia emerges as a fundamental yet underrecognized contributor to inadequate wound repair and subsequent scar failure. Connective tissue dysplasia encompasses a broad spectrum of inherited and acquired disorders characterized by abnormal synthesis, assembly, or degradation of extracellular matrix components, particularly collagen, elastin, and associated proteins. These conditions affect approximately 1 in 5000 individuals worldwide, with varying degrees of clinical severity and organ system involvement. The uterus, composed predominantly of smooth muscle interspersed with significant connective tissue elements, demonstrates particular vulnerability to dysplastic changes that compromise structural integrity and functional capacity.

The pathophysiological relationship between connective tissue abnormalities and uterine scar insufficiency involves complex interactions among genetic predisposition, hormonal influences,





mechanical stress, and environmental factors. Understanding these mechanisms has become increasingly important as reproductive medicine advances toward personalized care approaches that account for individual patient characteristics and risk factors. Recent advances in molecular biology and genetic testing have enhanced our ability to identify patients at elevated risk for scar complications, enabling implementation of targeted preventive strategies and optimized management protocols. Contemporary evidence suggests that connective tissue dysplasia may be significantly more prevalent among women experiencing uterine scar complications than previously recognized, with emerging research demonstrating subclinical forms of dysplasia that manifest primarily during periods of physiological stress such as pregnancy and wound healing. This recognition has profound implications for preconceptional counseling, antenatal care planning, and delivery management decisions.

### MAIN PART

The fundamental pathology underlying connective tissue dysplasia involves disrupted synthesis, processing, or assembly of collagen and other extracellular matrix proteins essential for tissue strength and integrity. Collagen, comprising approximately 25% of total body protein, exists in multiple forms with types I and III being predominant in reproductive tissues. Type I collagen provides tensile strength through thick, organized fibrils, while type III collagen contributes flexibility and elasticity through thinner, more randomly arranged fibers. The optimal ratio of these collagen types, typically 4:1 in healthy uterine tissue, becomes disrupted in dysplastic conditions. Genetic mutations affecting collagen synthesis pathways can involve structural genes encoding collagen alpha chains or regulatory genes controlling post-translational modifications, crosslinking, and matrix assembly. Classical connective tissue disorders such as Ehlers-Danlos syndrome demonstrate mutations in collagen type V, lysyl hydroxylase, or tenascin-X genes, resulting in defective collagen processing and abnormal fiber formation. However, recent research has identified numerous variant forms and previously unrecognized mutations that may manifest primarily during periods of increased tissue stress.

The role of matrix metalloproteinases and their tissue inhibitors represents another crucial aspect of connective tissue homeostasis relevant to uterine scar formation. Matrix metalloproteinase-2 and matrix metalloproteinase-9 regulate collagen turnover and remodeling during wound healing, while tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 modulate proteolytic activity. Dysregulation of this balance, commonly observed in connective tissue dysplasia, leads to excessive collagen degradation or inadequate remodeling, compromising scar strength and durability. Hormonal influences during pregnancy further complicate connective tissue metabolism in susceptible individuals. Estrogen and progesterone significantly affect collagen synthesis and crosslinking, with progesterone particularly influencing uterine tissue compliance and strength. Relaxin, produced in increasing quantities during pregnancy, promotes collagen remodeling and tissue softening through upregulation of metalloproteinase activity. In patients with underlying connective tissue abnormalities, these physiological changes may precipitate tissue failure under mechanical stress.

The clinical presentation of connective tissue dysplasia in obstetric patients ranges from subtle signs requiring careful evaluation to obvious systemic manifestations affecting multiple organ systems.





Cutaneous features including hyperextensibility, easy bruising, delayed wound healing, and atrophic scarring often provide initial clues to underlying connective tissue abnormalities. Joint hypermobility, particularly affecting large joints, may be present in varying degrees and can be quantified using standardized assessment tools such as the Beighton score. Cardiovascular manifestations of connective tissue dysplasia include mitral valve prolapse, aortic root dilatation, and arterial fragility, which may become clinically apparent during pregnancy due to increased blood volume and cardiac output. Uterine artery abnormalities and increased risk of spontaneous vascular rupture have been documented in patients with severe forms of connective tissue dysplasia, emphasizing the need for comprehensive cardiovascular evaluation in suspected cases. Previous obstetric history provides valuable insights into connective tissue integrity, with patterns of prolonged labor, cervical insufficiency, premature rupture of membranes, and wound healing complications suggesting underlying dysplastic processes. Women with history of multiple pregnancy losses, particularly those occurring in the second trimester, may have unrecognized connective tissue abnormalities affecting uterine and cervical competence. Family history remains a critical component of risk assessment, as most forms of connective tissue dysplasia demonstrate hereditary patterns with varying degrees of penetrance and expressivity. Detailed pedigree analysis may reveal affected family members with previously undiagnosed conditions or subclinical manifestations that become apparent only under specific circumstances such as pregnancy or surgical stress.

Normal uterine wound healing following cesarean section involves a complex cascade of cellular and molecular events orchestrated through carefully regulated phases of hemostasis, inflammation, proliferation, and remodeling. The initial hemostatic response involves platelet aggregation and fibrin clot formation, providing a temporary scaffold for subsequent cellular migration and tissue repair. Inflammatory mediators recruit neutrophils, macrophages, and lymphocytes to the wound site, initiating the clearance of debris and foreign material while releasing growth factors and cytokines essential for healing progression. The proliferative phase involves fibroblast migration, proliferation, and collagen synthesis, with initial deposition of type III collagen providing early structural support. Angiogenesis occurs concurrently, establishing vascular supply necessary for tissue oxygenation and nutrient delivery. Myofibroblasts contribute to wound contraction and early scar formation through actin-myosin interactions that reduce wound surface area and promote tissue approximation. Remodeling represents the final and most prolonged phase of wound healing, extending months to years following initial injury. During this phase, type III collagen is gradually replaced by stronger type I collagen through controlled synthesis and degradation processes. Collagen crosslinking increases progressively, enhancing tensile strength and scar durability. The balance between collagen synthesis and degradation determines ultimate scar quality and functional capacity. In patients with connective tissue dysplasia, multiple aspects of this healing cascade become disrupted. Abnormal collagen synthesis results in production of structurally defective proteins with reduced tensile strength and altered crosslinking capacity. Impaired growth factor signaling may delay cellular migration and proliferation, prolonging inflammatory phases and increasing risk of infection or dehiscence. Dysregulated metalloproteinase activity can lead to excessive collagen degradation during remodeling, preventing achievement of adequate scar strength.

Contemporary diagnostic evaluation of suspected connective tissue dysplasia requires a comprehensive multidisciplinary approach incorporating clinical assessment, biochemical testing,





imaging studies, and genetic analysis. The clinical evaluation begins with detailed history taking, focusing on personal and family history of connective tissue manifestations, previous surgical complications, and obstetric outcomes. Physical examination should include systematic assessment of skin characteristics, joint mobility, cardiovascular features, and previous surgical scars. Biochemical markers of collagen metabolism provide valuable objective evidence of connective tissue abnormalities. Serum and urinary levels of hydroxyproline, pyridinoline, and pyrrole crosslinks reflect collagen turnover rates and may be elevated in active dysplastic processes. Matrix metalloproteinase activity and tissue inhibitor levels can be measured through specialized assays, providing insights into remodeling balance and potential therapeutic targets. Advanced imaging modalities have enhanced our ability to assess uterine scar integrity and identify patients at risk for complications. High-resolution ultrasound with Doppler evaluation can detect scar thinning, niche formation, and vascular abnormalities that predict increased rupture risk. Magnetic resonance imaging provides superior soft tissue contrast and can identify subtle structural abnormalities not apparent on ultrasound examination. Three-dimensional imaging techniques allow comprehensive assessment of scar architecture and relationship to surrounding structures. Genetic testing has become increasingly important in diagnosing connective tissue dysplasia, with expanding panels available for screening known mutations associated with various subtypes. Whole exome sequencing and chromosomal microarray analysis can identify novel mutations or chromosomal abnormalities in patients with suspected but unclassified connective tissue disorders. Genetic counseling should accompany testing to ensure appropriate interpretation of results and discussion of inheritance patterns and recurrence risks.

The management of pregnant women with connective tissue dysplasia requires individualized care plans developed through multidisciplinary collaboration involving maternal-fetal medicine specialists, geneticists, anesthesiologists, and other relevant subspecialists. Preconceptional counseling plays a crucial role in risk assessment and preparation for pregnancy, allowing optimization of maternal health status and development of comprehensive care plans prior to conception. Antenatal surveillance protocols for patients with connective tissue dysplasia typically involve increased frequency of clinical assessments, specialized imaging studies, and laboratory monitoring. Serial ultrasound evaluations focus on fetal growth, amniotic fluid volume, and uterine scar integrity assessment. Cervical length measurements may be indicated due to increased risk of cervical insufficiency in patients with connective tissue abnormalities. Maternal echocardiography should be considered to evaluate for cardiovascular complications that may affect pregnancy management decisions. Nutritional support represents an important therapeutic intervention, with evidence suggesting that vitamin C, vitamin E, zinc, and copper supplementation may improve collagen synthesis and wound healing in patients with connective tissue disorders. Adequate protein intake ensures availability of amino acids essential for collagen production, while specific supplements such as glycine and proline may provide additional benefits for patients with severe dysplastic changes. Delivery planning requires careful consideration of individual risk factors, previous obstetric history, and current pregnancy characteristics. While vaginal delivery may be appropriate for some patients with mild connective tissue abnormalities, cesarean section is often recommended for those with severe dysplasia or previous uterine scar complications. The timing of delivery may need to be individualized based on fetal maturity and maternal risk factors, with some







patients benefiting from delivery prior to the onset of labor to minimize stress on compromised tissues.

Recent advances in regenerative medicine and tissue engineering offer promising approaches for enhancing wound healing and scar formation in patients with connective tissue dysplasia. Stem cell therapy has demonstrated potential for improving tissue repair through paracrine signaling mechanisms that enhance local cellular function and promote healing. Mesenchymal stem cells derived from bone marrow, adipose tissue, or amniotic fluid have shown particular promise in preclinical studies examining uterine tissue repair and regeneration. Gene therapy approaches targeting specific molecular defects underlying connective tissue dysplasia represent an emerging therapeutic frontier. Viral vector delivery systems can potentially introduce functional copies of defective genes or modify gene expression to improve collagen synthesis and matrix assembly. While still in early developmental stages, these approaches offer hope for addressing the fundamental pathophysiology rather than merely managing symptoms and complications. Biomaterial scaffolds designed to support tissue regeneration and provide temporary mechanical support during healing have shown promise in experimental models of uterine repair. These scaffolds can be engineered to deliver growth factors, cytokines, or cellular components in controlled fashion, optimizing the local environment for tissue regeneration. Biodegradable materials that gradually dissolve as natural tissue strength develops represent particularly attractive options for clinical application. Pharmacological interventions targeting specific aspects of collagen metabolism and wound healing continue under investigation. Matrix metalloproteinase inhibitors may help preserve collagen integrity during periods of increased turnover, while growth factor supplementation could enhance cellular responses in patients with impaired healing capacity. Antioxidant therapies may reduce oxidative stress that contributes to connective tissue damage and impaired repair processes.

Contemporary clinical studies have consistently demonstrated increased risks for uterine scar complications in patients with diagnosed or suspected connective tissue dysplasia. Large retrospective cohort studies report uterine rupture rates of 2-5% in patients with classical connective tissue disorders compared to 0.5-1% in the general population with previous cesarean section. These elevated risks persist across different subtypes of connective tissue dysplasia, although specific risk levels vary based on disease severity and affected organ systems. Maternal morbidity associated with scar complications extends beyond immediate rupture events to include increased rates of blood transfusion, emergency hysterectomy, intensive care unit admission, and prolonged hospitalization. Long-term complications such as chronic pain, adhesion formation, and subsequent fertility problems occur more frequently in patients with connective tissue abnormalities, emphasizing the importance of preventive strategies and optimized management approaches. Perinatal outcomes in pregnancies complicated by maternal connective tissue dysplasia demonstrate increased risks for preterm delivery, growth restriction, and neonatal complications. While some of these risks relate directly to maternal condition severity, others result from management decisions such as planned early delivery to minimize maternal risks. Careful balance between maternal and fetal considerations requires individualized assessment and shared decision-making processes. Evidence-based recommendations for managing patients with connective tissue dysplasia emphasize the importance of early identification, comprehensive risk assessment, and individualized care planning. Professional organizations increasingly recognize the need for specialized protocols addressing this patient





population, with recent guidelines incorporating recommendations for genetic testing, multidisciplinary consultation, and enhanced surveillance protocols.

In conclusion, the link between connective tissue dysplasia and uterine scar insufficiency involves genetic, molecular, and clinical factors that heighten obstetric risks. Impaired collagen synthesis and wound healing increase the likelihood of scar complications, requiring specialized care. Advances in imaging, biochemical tests, and genetic screening help identify high-risk patients, though challenges remain in standardizing diagnostics and treatment. Subclinical forms of dysplasia during pregnancy demand greater clinical attention. Future care will emphasize personalized approaches, regenerative therapies, and improved surgical techniques. A deeper understanding of these mechanisms supports better counseling, management, and maternal-perinatal outcomes.

### References:

1. Henderson JT, Webber EM, Sawaya GF. Screening for Connective Tissue Disorders in Adults: Evidence Report and Systematic Review. *Journal of the American Medical Association*. 2022;327(11):15
2. Malek S, Reinhart HA, Pearson GD. The prevalence and impact of connective tissue dysplasia on pregnancy outcomes: a systematic review. *American Journal of Obstetrics and Gynecology*. 2021;224(3):267-278.
3. Rodriguez-Lopez J, Martinez-Perez O, Couto D, et al. Uterine rupture and connective tissue disorders: molecular mechanisms and clinical implications. *Obstetrics and Gynecology International*. 2023;2023:1247892.
4. Chen KH, Wang CJ, Lee WL, et al. Matrix metalloproteinases and tissue inhibitors in uterine scar formation after cesarean section. *Reproductive Sciences*. 2022;29(4):1156-1164.
5. Thompson JA, Roberts CL, Morris J, et al. The association between Ehlers-Danlos syndrome and obstetric complications: a population-based cohort study. *BJOG: An International Journal of Obstetrics and Gynaecology*. 2021;128(8):1326-1334.
6. Van Uum CC, Ritchie HL, Teede HJ, et al. Collagen metabolism biomarkers in pregnancy: implications for maternal and fetal outcomes. *Clinica Chimica Acta*. 2023;538:45-52.
7. Singh N, Tripathi R, Mala YM, et al. Genetic factors in uterine scar dehiscence: emerging evidence and clinical correlations. *Journal of Maternal-Fetal and Neonatal Medicine*. 2022;35(18):3542-3549.
8. Li X, Zhang Y, Zhao L, et al. Three-dimensional ultrasound assessment of cesarean scar integrity in women with connective tissue disorders. *Ultrasound in Obstetrics and Gynecology*. 2021;58(4):578-585.
9. Kumar A, Begum J, Carstairs SD, et al. Management strategies for pregnant women with hereditary connective tissue disorders: a multidisciplinary approach. *Maternal and Child Health Journal*. 2023;27(2):234-245.
10. Park JS, Kim EH, Lee SM, et al. Stem cell therapy for uterine tissue regeneration: current status and future perspectives. *Cells*. 2022;11(6):924.
11. Wilson RM, Gordon KC, Ripley DL, et al. Biomaterial approaches to treating uterine scar defects: from bench to bedside. *Advanced Healthcare Materials*. 2021;10(21): e2100849.

